Braverman Test

Overview

Braverman Test is an online service offering a self-assessment questionnaire to evaluate the strength and deficits of four primary neurotransmitters: dopamine, serotonin, GABA, and acetylcholine. The test generates a report emailed to users within 10 minutes, providing insights into neuro-biochemical profiles related to mental health, mood, cognition, and performance. It positions itself as a tool for personalized insights based on patterns from user responses, distinct from traditional personality tests, though not intended as a medical diagnosis.

History

The Braverman Test originates from methodologies developed by Eric R. Braverman, an American physician born in 1957, who founded PATH Medical in New York City focusing on brain health and supplements. The test draws from over 50 years of observations and experiments published and reviewed by neuroscientists. It is offered via bravermantest.com and bravermantest.net as a commercial online assessment.

Product Lines

Manufacturing

No physical products are manufactured; the service is a digital questionnaire and automated report generation hosted online.

Notable Products

• Braverman Test Part A - Determines power levels of four primary neurotransmitters based on user responses.
• Braverman Test Part B - Identifies deficits and imbalances in the neuro-biochemical profile.
• Neurotransmitter Profile Report - Automated PDF report emailed post-test with insights on dopamine, serotonin, GABA, and acetylcholine.
• Free Personality Type Assessment - Basic true/false questionnaire for dominant brain temperament.

Reputation

The Braverman Test is viewed as an accessible self-assessment tool for neurotransmitter insights but criticized by sources like Quackwatch for association with Eric Braverman's PATH Medical, accused of promoting questionable supplements and quackery. It is not recognized as a clinical diagnostic by medical professionals and serves mainly as an educational starting point for discussions with doctors. Some academic references note its basis in monoamine neurochemical research, though validation remains limited.